Astria Therapeutics Inc (ATXS)

09:49 AM

What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional

09:49 AM

08:08 AM

Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com

08:08 AM

04:44 AM

What analysts say about Astria Therapeutics Inc. stockTriple-digit return opportunities - Autocar Professional

04:44 AM

Jul 22, 2025

Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

Published on: 2025-07-19 19:06:02 - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser

Jul 18, 2025

Jul 16, 2025

why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser

Jul 16, 2025

Jul 16, 2025

How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser

Jul 16, 2025

Jul 15, 2025

What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru

Jul 15, 2025

Jul 15, 2025

Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser

Jul 15, 2025

Jul 15, 2025

Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha

Jul 15, 2025

Jul 09, 2025

Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest

Jul 09, 2025

Jul 08, 2025

Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jul 08, 2025

Jul 07, 2025

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace

Jul 07, 2025

Jul 07, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World

Jul 07, 2025

Jul 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace

Jul 03, 2025

Jun 29, 2025

Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 29, 2025

Jun 18, 2025

(ATXS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025

Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace

Jun 18, 2025

Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus

Jun 18, 2025

Jun 18, 2025

Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan

Jun 18, 2025

Jun 16, 2025

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace

Jun 16, 2025

Jun 15, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World

Jun 15, 2025

Jun 15, 2025

HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World

Jun 15, 2025

Jun 14, 2025

Astria Therapeutics (ATXS) Receives Reiterated Buy Rating and $1 - GuruFocus

Jun 14, 2025

Jun 13, 2025

Astria Therapeutics (ATXS) Reports Promising Results for Navenib - GuruFocus

Jun 13, 2025

Jun 13, 2025

Astria Therapeutics Announces Positive Initial Results from the - GuruFocus

Jun 13, 2025

Jun 13, 2025

Astria Therapeutics Says New Data Back Navenibart Dose Regimen for Hereditary Angioedema - MarketScreener

Jun 13, 2025